Segment Information (Tables)

12 Months Ended

Dec. 31, 2024

The following tables present financial information for the Company’s reportable segments for the periods indicated (in thousands):


	Year Ended December 31, 2024
	Finance Receivables		Pharmaceutical Development and Other		Holding Company and Other		Consolidated
Revenue	$	40,787	$	3,616	$	—	$	44,403
Other revenue	553		31		—		584
Provision for credit losses	12,756		—		—		12,756
Loss on impairment of intangible assets	—		5,771		—		5,771
Interest expense	1,078		8		3,599		4,685
Pharmaceutical manufacturing, research and development	—		2,203		—		2,203
Change in fair value of acquisition-related contingent consideration	—		(4,900)		—		(4,900)
Depreciation and amortization expense	—		1,316		83		1,399
General and administrative expense	449		2,967		8,071		11,487
Other income (expense), net	7,194		—		(408)		6,786
Income tax expense	—		—		4,884		4,884
Net income (loss)	34,251		(3,718)		(17,045)		13,488


	Year Ended December 31, 2023
	Finance Receivables		Pharmaceutical Development and Other		Holding Company and Other		Consolidated
Revenue	$	36,346	$	1,202	$	—	$	37,548
Other revenue	204		2		6		212
Provision for credit losses	1,912		—		—		1,912
Impairment of goodwill	—		8,404		—		8,404
Interest expense	982		3		864		1,849
Pharmaceutical manufacturing, research and development expense	—		3,436		—		3,436
Depreciation and amortization expense	—		2,525		52		2,577
Change in fair value of acquisition-related contingent consideration	—		(6,300)		—		(6,300)
General and administrative expense	527		2,875		7,830		11,232
Other expense, net	(13)		(24)		—		(37)
Income tax benefit	—		—		(1,274)		(1,274)
Net income (loss)	33,116		(9,763)		(7,466)		15,887

The following table presents total assets for the Company's reportable segments for the periods indicated (in thousands):


	December 31,
	2024		2023
Total Assets
Finance Receivables	$	299,248	$	288,735
Pharmaceutical Development and Other	7,786		14,375
Holdings Company and Other	25,201		31,144
Total	$	332,235	$	334,254